Alerts
One email when a status changes.
What sends an email
- A status flips. A compound on this site becomes legal to compound, gets approved, or loses either.
- A committee votes. The FDA’s Pharmacy Compounding Advisory Committee votes on a compound on this site.
- A new compound page goes up.
Next known event
Before the end of February 2027, the FDA’s advisory committee is due to review five more compounds: Dihexa, GHK-Cu, LL-37, Melanotan II and PEG-MGF. The FDA tracker has the dates as they are set.
Get the email
Sent through Substack: the button opens it in a new tab to confirm. Every email has an unsubscribe link.
No newsletter. No opinions. No vendors.